75284 Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices 

1 12 U.S.C. 1828(c). The FDIC is the responsible 

agency if the acquiring, assuming, or resulting bank 

is to be a State nonmember insured bank or a State 

savings association. 

Insurance Corporation, 550 17th Street 

NW, Washington, DC 20429. 

• Hand Delivery: Comments may be 

hand-delivered to the guard station at 

the rear of the 17th Street NW building 

(located on F Street NW), on business 

days between 7 a.m. and 5 p.m. 

All comments should refer to the 

relevant OMB control number. A copy 

of the comments may also be submitted 

to the OMB desk officer for the FDIC: 

Office of Information and Regulatory 

Affairs, Office of Management and 

Budget, New Executive Office Building, 

Washington, DC 20503. 

FOR FURTHER INFORMATION CONTACT: 

Jennifer Jones, Regulatory Counsel, 202– 

898–6768, jennjones@fdic.gov, MB– 

3078, Federal Deposit Insurance 

Corporation, 550 17th Street NW, 

Washington, DC 20429. 

SUPPLEMENTARY INFORMATION: 

Proposal to renew the following 

currently approved collection of 

information: 

1. Title: Interagency Bank Merger 

Application. 

OMB Number: 3064–0015. 

Form Number: 6220/01 

Affected Public: FDIC-insured 

depository institutions. 

Burden Estimate: 

Information collection description Type of 

burden 

Obligation to 

Respond 

Estimated 

number of 

respondents 

Estimated 

frequency of 

responses 

Estimated 

time per 

response 

(hours) 

Estimated 

annual burden 

(hours) 

Interagency Bank Merger Act Application—Affiliated Transactions.Reporting ....... Mandatory ...... 103 On Occasion .. 19 1,957 

Interagency Bank Merger Act Application—Nonaffiliated Transactions.Reporting ....... Mandatory ...... 117 On Occasion .. 31 3,627 

Total Estimated Annual Burden ....... ........................ ........................ ........................ ........................ ........................ 5,584 

General Description of Collection: 

Section 18(c) of the Federal Deposit 

Insurance Act (FDI Act) requires an 

insured depository institution (IDI) that 

wishes to merge or consolidate with any 

other IDI or, either directly or indirectly, 

acquire the assets of, or assume liability 

to pay any deposits made in, any other 

IDI, to apply for the prior written 

approval of the responsible agency (the 

FDIC; the Board of Governors of the 

Federal Reserve (FRB); or the Office of 

the Comptroller of the Currency 

(OCC)).1 Section 18(c) further requires 

FDIC approval in connection with any 

merger transaction involving an IDI and 

a non-insured entity. 

The Interagency Bank Merger Act 

Application Form (Application Form) is 

used by the FDIC, the FRB, and the OCC 

for applications under section 18(c) of 

the FDI Act. The Application Form may 

be used for any merger transaction 

subject to section 18(c). There is a 

different level of burden for each of the 

two types of merger transactions, 

nonaffiliated and affiliated. An affiliate 

transaction refers to a merger, 

consolidation, other combination, or 

transfer of any deposit liabilities, 

between an IDI and another entity 

controlled by the same parent company, 

regardless of whether the other entity is 

FDIC-insured. It includes a business 

combination between an IDI and an 

affiliated interim institution. Applicants 

proposing affiliate transactions are not 

required to complete questions 12 

through 14 of the Application Form. If 

the merging entities are not controlled 

by the same parent company, the merger 

transaction is considered nonaffiliated, 

and the applicant must complete the 

entire application form. 

The FDIC Supplement to the 

Interagency Bank Merger Act 

Application Form (Supplement) 

requires each applicant to provide 

information that delineates the relevant 

geographic market(s) and describes the 

competition in the relevant geographic 

market(s). The information collected 

focuses on the relevant geographic 

market(s) where the applicant and the 

entity to be acquired provide banking 

products or services. The Supplement 

includes specific instructions to 

facilitate a comprehensive competitive 

analysis relative to transactions between 

nonaffiliated entities. 

There is no change in the method or 

substance of the collection. The 62-hour 

decrease in burden hours is the result of 

updated data available. 

Request for Comment 

Comments are invited on: (a) whether 

the collection of information is 

necessary for the proper performance of 

the FDIC’s functions, including whether 

the information has practical utility; (b) 

the accuracy of the estimate of the 

burden of the information collection, 

including the validity of the 

methodology and assumptions used; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. All comments will become 

a matter of public record. 

Federal Deposit Insurance Corporation. 

Dated at Washington, DC, on October 30, 

2023. 

Debra A. Decker, 

Executive Secretary. 

[FR Doc. 2023–24252 Filed 11–1–23; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices 75285 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than December 4, 2023. 

A. Federal Reserve Bank of Boston 

(Prabal Chakrabarti, Senior Vice 

President) 600 Atlantic Avenue, Boston, 

Massachusetts 02210–2204. Comments 

can also be sent electronically to 

BOS.SRC.Applications.Comments@

bos.frb.org: 

1. Mutual Bancorp MHC, Hyannis, 

Massachusetts; to merge with Fidelity 

Mutual Holding Company Leominster, 

Massachusetts, and thereby indirectly 

acquire Life Design Holding Company, 

Hyannis, Massachusetts, and Fidelity 

Co-Operative Bank, Leominster, 

Massachusetts. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2023–24243 Filed 11–1–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Trauma Informed Care 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submission. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Trauma Informed Care, which is 

currently being conducted by the 

AHRQ’s Evidence-based Practice 

Centers (EPC) Program. Access to 

published and unpublished pertinent 

scientific information will improve the 

quality of this review. 

DATES: Submission Deadline on or 

before December 4, 2023. 

ADDRESSES: 

Email submissions: epc@ahrq.hhs.gov 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Carper, Telephone: 301–427–1656 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Trauma Informed Care. 

AHRQ is conducting this review 

pursuant to Section 902 of the Public 

Health Service Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Trauma Informed Care. 

The entire research protocol is available 

online at: https://effectivehealthcare.

ahrq.gov/products/trauma-informedcare/protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Trauma Informed Care 

helpful: 

D A list of completed studies that 

your organization has sponsored for this 

topic. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements, if relevant: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to follow-up/withdrawn/ 

analyzed, effectiveness/efficacy, and 

safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

topic. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including, if relevant, a study 

number, the study period, design, 

methodology, indication and diagnosis, 

proper use instructions, inclusion and 

exclusion criteria, and primary and 

secondary outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this topic and an index 

outlining the relevant information in 

each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on topics not included in 

the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://www.effectivehealthcare.

ahrq.gov/email-updates. 

The review will answer the following 

questions. This information is provided 

as background. AHRQ is not requesting 

that the public provide answers to these 

questions. 

Key Questions (KQ) 

TIC for Adult Patients/Clients 

• KQ 1. What is the evidence of 

benefits and/or harms of TIC on 

outcomes for patients/clients? 

Æ KQ 1a. Which components (e.g., 

education and training of providers about 

trauma, screening patients, delivering pointof-care interventions [note this is not meant 

to include established evidence-based 

treatments for trauma-related disorders], 

referring patients/clients for various forms of 

additional assessment and treatment for 

indicated needs) of TIC models, and 

organizational and practice characteristics, 

are associated with benefits and/or harms? 

Æ KQ 1b. Do outcomes vary by patient/ 

client or clinical or organizational 

characteristics, including the nature, extent 

and timing of exposure (e.g., recent or 

ongoing vs. prior exposure in childhood)? 

TIC for Child and Adolescent Patients/ 

Clients 

• KQ 2. What is the evidence of 

benefits and/or harms of TIC on 

outcomes for patients/clients? 

Æ KQ 2a. Which components (e.g., 

education and training of providers about 

trauma, screening patients, delivering pointof-care interventions [note this is not meant 

to include indicated evidence-based 

treatments for trauma-related disorders], 

referring clients for various forms of 

additional assessment and treatment for 

indicated needs) of TIC models, 

organizational and practice characteristics, 

are associated with benefits and/or harms? 


khammond on DSKJM1Z7X2PROD with NOTICES